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Complex Interplay between HIV-1 Capsid and MX2-Independent
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Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germanya; Institute for Medical Virology, University Hospital Frankfurt/Main,
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Hospital, Karolinska Hospital, Stockholm, Swedend
ABSTRACT
Type I interferons (IFNs), including IFN-, upregulate an array of IFN-stimulated genes (ISGs) and potently suppress Human
immunodeficiency virus type 1 (HIV-1) infectivity in CD4 T cells, monocyte-derived macrophages, and dendritic cells. Re-
cently, we and others identified ISGmyxovirus resistance 2 (MX2) as an inhibitor of HIV-1 nuclear entry. However, additional
antiviral blocks exist upstream of nuclear import, but the ISGs that suppress infection, e.g., prior to (or during) reverse tran-
scription, remain to be defined.We show here that the HIV-1 CAmutations N74D and A105T, both of which allow escape from
inhibition byMX2 and the truncated version of cleavage and polyadenylation specific factor 6 (CPSF6), as well as the cyclophilin
A (CypA)-binding loopmutation P90A, all increase sensitivity to IFN--mediated inhibition. Using clustered regularly inter-
spaced short palindromic repeat (CRISPR)/Cas9 technology, we demonstrate that the IFN- hypersensitivity of these mutants in
THP-1 cells is independent of MX2 or CPSF6. As expected, CypA depletion had no additional effect on the behavior of the P90A
mutant but modestly increased the IFN- sensitivity of wild-type virus. Interestingly, the infectivity of wild-type or P90A virus
could be rescued from theMX2-independent IFN--induced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its
nonimmunosuppressive analogue SDZ-NIM811, indicating that Cs-sensitive host cell cyclophilins other than CypA contribute
to the activity of IFN--induced blocks. We propose that cellular interactions with incoming HIV-1 capsids help shield the virus
from recognition by antiviral effector mechanisms. Thus, the CA protein is a fulcrum for the dynamic interplay between cell-
encoded functions that inhibit or promote HIV-1 infection.
IMPORTANCE
HIV-1 is the causative agent of AIDS. During acute HIV-1 infection, numerous proinflammatory cytokines are produced, includ-
ing type I interferons (IFNs). IFNs can limit HIV-1 replication by inducing the expression of a set of antiviral genes that inhibit
HIV-1 at multiple steps in its life cycle, including the postentry steps of reverse transcription and nuclear import. This is ob-
served in cultured cell systems, as well as in clinical trials in HIV-1-infected patients. The identities of the cellular antiviral fac-
tors, their viral targets, and the underpinning mechanisms are largely unknown.We show here that the HIV-1 Capsid protein
plays a central role in protecting the virus from IFN-induced inhibitors that block early postentry steps of infection. We further
show that host cell cyclophilins play an important role in regulating these processes, thus highlighting the complex interplay
between antiviral effector mechanisms and viral survival.
Acute human immunodeficiency virus type 1 (HIV-1) infec-tion presents with a dramatic loss of CD4 T cells, which is
accompanied by the production of large quantities of cytokines (1,
2). Studies of simian immunodeficiency virus (SIV) infection of
macaques suggest that this cytokine production contributes to
initial limitation of viral spread, lowering the viral burden to a
level defining the virological set point and facilitating the partial
recovery of CD4 T cell counts (3).
Type I interferons (IFNs), a group of cytokines releasedmainly
by plasmacytoid dendritic cells during acute virus infection (4),
include 13 different subtypes of IFN-, as well as IFN-, IFN-ε,
IFN-, and IFN- (5), and have long been known to potently
suppress HIV-1 replication in certain types of natural target cells
(6–19). In addition to treating infections by other human patho-
gens (e.g., hepatitis C virus [HCV]), recombinant IFN- therapy
has also been investigated as a treatment strategy for HIV-1 infec-
tion. Although a substantial reduction in viral load was observed
in chronic infection, viral rebound over time suggests that HIV-1
in-patient evolution may overcome IFN--induced antiviral host
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factors (20, 21). It is therefore likely that different HIV-1 strains
have different sensitivities to type I IFNs. Comparison of diverse
HIV-1 strains suggested that transmitted founder (T/F) viruses of
subtype B, but not subtype C, show a relative resistance to IFN--
induced blocks, arguing that type I IFNs may play an important
role in limiting transmission in a subtype-defined context (22–
24). The viral determinants for partially overcoming the IFN--
induced blocks to HIV-1 are unknown. It is therefore important
to identify the host cell effectors induced by type I IFNs and to
understand themolecular interplay between the host and the virus
after IFN- treatment.
The addition of type I IFNs to cultured CD4 T cells or mono-
cyte-derived macrophages (MDMs) changes the expression pro-
file of thousands of host genes (25) and induces the production of
many antiviral proteins, only a few of which have been character-
ized in detail (reviewed in references 26 and 27). Preincubation of
susceptible cells with type I IFNs blocks HIV-1 infection at an
early step prior to or during reverse transcription (17, 28–31). The
cellular host factors mediating this effect are unknown. One re-
cently discovered type I IFN-induced factor that inhibits HIV-1 is
the GTPasemyxovirus resistance 2 (MX2 [also calledMXB]) (32–
34). MX2 blocks HIV-1 after reverse transcription at the level of
nuclear entry, suggesting that IFN-induced host cell barriers are
likely to interferewithHIV-1 infection atmultiple early steps (32).
Intriguingly, MX2 restriction of HIV-1 appears to be sensitive to
changes in theHIV-1Capsid protein (Gagp24/CA), an observation
reminiscent of restriction by the bona fide CA binding factor
TRIM5 (32–35). Consistent with these observations, in vitro
studies suggest direct binding of MX2 to CA (36, 37). In addition,
certain T/F viruses show some degree of resistance to the antiviral
activity of MX2, suggesting a functional role of MX2 in limiting
HIV-1 transmission (38).
The HIV-1 CA protein is essential for efficient infection and is
genetically fragile, i.e., many amino acid residues are highly con-
served and many single amino acid substitutions can abrogate
viral infectivity (39, 40). Most likely, this is due to the central
function of CA in the assembly and architecture of the viral core, a
complex conical fullerene-like structure consisting of hexameric
and pentameric CA subcomplexes (41–45). Amino acid substitu-
tions in CA can affect capsid assembly, stability, and uncoating
(46, 47), reverse transcription (48), usage of a productive nuclear
import pathway (47, 49), and infection of nondividing cells (50),
as well as integration site selection (51), processes that are all in-
terlinked.
SomeHIV-1mutants carrying changes in CA, includingN74D
or P90A, have been shown to induce IFN- secretion inMDMs or
dendritic cells as a result of cyclic GMP-AMP synthase (cGAS)-
mediated recognition of reverse transcription intermediates, indi-
cating that the capsid shell may ordinarily shield viral DNA from
recognition by innate immune sensors (52–54). The inability of
these CAmutant viruses to replicate efficiently in MDMs (51, 55)
may therefore be partially explained by a cascade of innate sensing,
type I IFN secretion, and induction of IFN-stimulated genes
(ISGs).
TheHIV-1 CAmutantN74D escapes inhibition by a truncated
version of cleavage and polyadenylation specific factor 6 (CPSF6-
358) and does not bind a CPSF6-derived peptide in vitro (49, 56,
57). Similarly, CA mutant A105T is not restricted by CPSF6-358
(58). The cyclophilin-binding loop CA mutant P90A binds with
reduced affinity to peptidylprolyl cis-trans isomerase A, also
known as cyclophilin A (CypA), and is resistant to CypA-medi-
ated isomerization of theG89-P90 peptide bond inCA (59–61). In
addition to CypA (62, 63) andCPSF6 (56, 57), HIV-1CAhas been
proposed to bind to the nuclear pore complex (NPC) protein
NUP153 (64), as well as to the cyclophilin domain ofNUP358 (51,
65), and binding-deficient CA mutants have been characterized.
All of the aforementioned host proteins have been invoked as
cofactors acting in early HIV-1 infection (49, 66–69).
While HIV-1 CA mutants can escape inhibition by ectopically
expressed MX2, we now demonstrate that the infectivities of the
HIV-1 CAmutants N74D, A105T, and P90A are hypersensitive to
IFN--induced suppression compared to wild-type virus. This
suggests that the susceptibility of viral determinants that are tar-
geted by IFN--induced MX2-independent blocks is increased
when capsid functionality is compromised. In addition, thisMX2-
independent IFN--induced postentry block can be relieved by
pharmacological inhibition of cyclophilins, suggesting a role of
host cell cyclophilins in the early type I IFN-induced suppression
of HIV-1 infection.We suggest that the CA protein and the capsid
core may therefore protect incoming HIV-1 nucleic acids from
detection by innate pattern recognition receptors (52, 53), as well
as IFN--induced effectors, thereby providing dual protection
against host defense.
MATERIALS AND METHODS
Cells. THP-1 cells were grown in RPMI 1640 GlutaMAX (Gibco) supple-
mented with 10% heat-inactivated fetal calf serum (FCS) and 100 U/ml
penicillin and 100 g/ml streptomycin. THP-1 cells were differentiated
with 25 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) for
24 h. The purification of primary blood mononuclear cells has been de-
scribed before (70). Primary CD4 T cells or CD14 monocytes were
derived from 50 ml of whole blood or from buffy coats and grown in
RPMI 1640 medium with GlutaMAX with 10% heat-inactivated FCS and
penicillin-streptomycin. CD4T cells were isolated using theCD4T cell
isolation kit II (Miltenyi Biotec) or the RosetteSep human CD4 T cell
enrichment cocktail (Stem Cell Technologies), activated with 100 IU/ml
interleukin-2 (IL-2; Biomol) and 2 g/ml phytohemagglutinin (PHA;
Sigma-Aldrich) for 3 days.MDMswere differentiated for 7 days using 100
ng/ml granulocyte-macrophage colony-stimulating factor (R&D Sys-
tems). 293T were grown in Dulbecco modified Eagle medium (DMEM-
GlutaMAX; Gibco) with 10% heat-inactivated FCS and penicillin-strep-
tomycin.
Plasmids and viral vectors. Vesicular stomatitis virus G protein
(VSV-G)-pseudotyped wild-type- or CA mutant green fluorescent pro-
tein (GFP)-encoding HIV-1 vectors were produced using the Gag-Pol-
encoding plasmid pCMV-R8.91, the GFP reporter vector pCSGW, and
the VSV-G-encoding plasmid pMD.G, which have been described before
(51). pCMV-R8.91-derived HIV-1 Gag-Pol plasmid encoding SIVMAC
CA has been described before (71). Full-length wild-type and CAmutant
HIV-1 GFP reporter viruses were generated from pNLENG-IRES-Nef
(51, 72). THP-1 clustered regularly interspaced short palindromic repeat
(CRISPR)/Cas cells were generated by transduction with VSV-G-pseu-
dotyped HIV-1 lentiviral particles produced using pCMV-R8.91,
pMD.G, and plentiCRISPRv2 (Addgene) (73, 74). Guide RNA encoding
oligonucleotides (MWG/Eurofins) were annealed and cloned into
BsmBI-linearized plentiCRISPRv2 according to the manufacturer’s
guidelines (Addgene). The oligonucleotides used were as follows (for-
ward/reverse): forMX2g1, caccgAATTGACTTCTCCTCCGGTA/aaacTA
CCGGAGGAGAAGTCAATTc; for MX2g2, caccgACAAGCCTTGGCC
CTACCGG/aaacCCGGTAGGGCCAAGGCTTGTc; for CPSF6g1,
caccgATAGACATTTACGCGGATGT/aaacACATCCGCGTAAAT
GTCTATc; for CPSF6g2, caccgCATCCGCGTAAATGTCTATG/aaacCA
TAGACATTTACGCGGATGc; for CPSF6g3, caccgGGACCACATAGAC
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Viral vector andHIV-1 production. 293T cells grown in 10-cmplates
were transfected at a confluence of approximately 70 to 80%with 4.5g of
viral vector plasmid, 3 g of pCMVR8.91, and 3 g of pMD.G using 4
g of polyethylenimine perg of DNA in 1ml of Opti-MEM (Gibco) per
plate. For VSV-G-pseudotyped full-length HIV-1 production, 8 g of
HIV-1 GFP reporter plasmid and 2 g of pMD.G were cotransfected per
plate. The mediumwas changed at 24 h posttransfection, the viruses were
harvested at 48 and 72 h posttransfection and passed through a 0.45-m-
pore-size filter, and the collections were pooled. Depending on the exper-
iment, viral supernatants were subjected to sucrose purification as de-
scribed previously (70).
Generation of CRISPR/Cas9 THP-1 cell clones. THP-1 cells were
transduced with VSV-G-pseudotyped HIV-1 lentiviral vector (LV) deliv-
ering plentiCRISPRv2 at an estimated multiplicity of infection (MOI) of
1. Transduced cell populations were selected with 1g/ml puromycin for
2 weeks. Single-cell clones were generated by limiting dilution and grown
in 96-well plates for at least 2 weeks in the absence of puromycin. MX2
gene disruption was validated by PCR amplification of the targeted
genomic region using the oligonucleotides AGCAAAGGAACATTGAGA
CTCTACTG (forward) and TTATTGTGGTGGGCTTACATGACAGC
(reverse).
Infections. A total of 5 	 105 THP-1 or CD4 T cells were plated in
100 l of medium per well in 96-well plates and treated for 24 h with
IFN-. Next, 100 l of supernatant containing VSV-G-pseudotyped
GFP-reporter lentiviral vectors or NL4.3GFP-reporter virus was added.
To compare different CA mutants with wild-type GFP reporter vector/
virus, we normalized viral input by 293T infectious titers or by units of
reverse transcriptase in the supernatant, as determined by a SYBR green
PCR-enhanced reverse transcriptase assay (SG-PERT) previously de-
scribed (75). Cells were fixed in 4% paraformaldehyde (PFA) 2 to 3 days
later, the infectivities were determined from the percentage of GFP cells
by flow cytometry using a FACSVerse (BD Biosciences), and the infec-
tious titers were determined on at least three different virus doses. The
average infectious titers were calculatedwith standard deviations depicted
as error bars. Experiments with MDMs were performed with 48-well
plates, seeding 5 	 105 monocytes per well prior to differentiation. For
analysis by flow cytometry, MDMs were trypsinized for at least 30 min,
resuspended, and fixed in 4% PFA. Virus titrations were usually per-
formed by 3-fold serial dilutions of the viral supernatant. In the case of
drug titration experiments (IFN- or cyclosporine [Cs]), a single dose of
supernatant containing reporter viruswas used, aiming for anMOI of1.
For experiments using Cs or SDZ-NIM811, drugs were added at the time
of infection with the reporter virus.
Immunoblotting and antibodies. Proteins were separated in Mini-
Protean TGX stain-free precast gels (Bio-Rad) at 120 V for 1 h and sub-
sequently subjected toUVactivation and quantitative gel imaging to com-
pare the amounts of loaded protein. Proteins were transferred to
nitrocellulose membranes using Trans-Blot Turbo transfer system (Bio-
Rad). The primary antibodies used were rabbit anti-MX1 (1:1,000; Pro-
teintech), rabbit anti-MX2 (1:1,000; Novusbio), rabbit anti-CypA SA296
(1:3,000; Biomol), mouse anti-alpha-tubulin (1:3,000; Sigma-Aldrich),
rabbit anti-CPSF6 (1:3,000; Abcam), and rabbit anti-MAPK (Erk1/2;
1:1,000; Cell Signaling). Goat anti-mouse or anti-rabbit IgG secondary
antibodies were coupled to horseradish peroxidase (Cell Signaling Tech-
nology), and proteins were detected using Pierce ECL Plus Western blot-
ting substrate (Thermo Scientific).
Drugs. SDZ-NIM811 was kindly provided by R. Bartenschlager
(Heidelberg University Hospital, Heidelberg, Germany). Cyclosporine
(Sandoz) was diluted in dimethyl sulfoxide (DMSO) to a stock of 1.0mM.
The IFN-2 (Roferon-A, IFN--2a) stock concentration was 6.0 	 106
IU/ml, and this was used at the indicated concentrations.
TaqMan qPCR. THP-1 cells were seeded at 106 cells per well in six-
well plates, treated or not with 500 IU/ml IFN- for 24 h, and infected the
next day with the same dose of wild-type or CAmutant viruses. The total
DNAwas isolated from the cells at 4 or 24 h postinfection using aQIAamp
extraction kit (Qiagen). TaqMan quantitative PCR (qPCR) was per-
formed using the GFP primers CAACAGCCACAACGTCTATATCAT/A
TGTTGTGGCGGATCTTGAAG (forward/reverse) and the probe FAM-
CCGACAAGCAGAAGAACGGCATCAA-TAMRA (where FAM is 6-
carboxyfluorescein and TAMRA is 6-carboxytetramethylrhodamine) and
the 2-long terminal repeat (2-LTR) circle primers AACTAGAGATCCCT
CAGACCCTTTT/CTTGTCTTCGTTGGGAGTGAATT (forward/reverse)
and the probe FAM-CTAGAGATTTTCCACACTGAC-TAMRA (76).
The samples were normalized either to the total DNA concentration or by
TaqMan qPCR for GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) with the primers GGCTGAGAACGGGAAGCTT/AGGGATCTCG
CTCCTGGAA (forward/reverse) and the probe FAM-TCATCAATGGA
AATCCCATCACCA-TAMRA. TaqMan qPCRs were performed using
the Applied Biosystems 7500 real-time PCR system (Applied Biosys-
tems).
RESULTS
HIV-1 CAmutants N74D or P90A display enhanced sensitivity
to IFN--induced blocks. Overexpression of the type I IFN-in-
duced protein MX2 blocks HIV-1 infection in a CA-sensitive
manner, and CA amino acid substitutions N74D or P90A reduce
the sensitivity of HIV-1 to ectopic MX2-mediated repression (32,
33).We reasoned that N74D or P90A changes in HIV-1 CAmight
therefore reduce the sensitivity of HIV-1 to IFN--induced
postentry blocks. To test this hypothesis, we treated the myeloid
cell line THP-1 with increasing amounts of IFN- and challenged
with equal doses of wild-type VSV-G-pseudotyped HIV-1 GFP
lentiviral vector (LV) or viruses with the CA mutants N74D or
P90A, as judged by their infectious titers on 293T cells, and deter-
mined the percentages of infected cells 2 days later. In untreated
THP-1 cells, no substantial differences in infectious titers were
detected between the wild type or the CA mutants (Fig. 1A, left
panel). Likewise, VSV-G-pseudotyped full-length NL4.3GFP re-
porter virus bearing wild-type CA or N74D or P90A mutant CA
showed similar titers in THP-1 cells (Fig. 1B, left panel). In con-
trast, the CA mutants N74D or P90A were suppressed up to ~10-
fold more efficiently by pretreatment with different concentra-
tions of IFN- (Fig. 1A and B, right panel).
We next examined these effects in MDMs or IL-2/PHA-acti-
vated CD4 T cells. We confirmed that CA mutants N74D or
P90A hadmodestly reduced infectivity inMDMs, as well as CD4
T cells, compared to the wild type (51, 55, 69) (Fig. 1C and D, left
panels). In both cell types, the N74D or P90A CA mutants were
inhibited more effectively by pretreatment with lower doses of
IFN- relative to wild-type virus (Fig. 1C andD, right panels). For
instance, in MDMs pretreated with 62.5 U of IFN-/ml, N74D or
P90A CA mutants were inhibited 
20-fold, whereas wild-type
HIV-1 GFP LVwas blocked
4-fold (Fig. 1C). The hypersensitiv-
ity of HIV-1 CA mutants was also observed with NL4.3GFP car-
rying the Ba-L Envelope and thus was independent of the entry
route (data not shown). In primary CD4 T cells, CA mutants
N74D or P90A were blocked 
3-fold more than the wild-type
virus at low IFN- doses (Fig. 1D). These results reveal thatHIV-1
CA mutants N74D or P90A have increased sensitivity to IFN--
induced blocks: this was unanticipated given their reduced sensi-
tivity to MX2-mediated inhibition (32). We therefore inferred
that the IFN--induced factors blocking HIV-1 CA mutants
N74D or P90A might function independently of MX2.
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The increased sensitivity of HIV-1 CAmutants to IFN--in-
duced blocks is independent of MX2. To demonstrate formally
that the increased sensitivity of HIV-1 CAmutants N74D or P90A
to IFN--induced blocks is independent ofMX2,we disrupted the
MX2 gene in THP-1 cells using two independent CRISPR guide
RNAs (MX2g1 and MX2g2). These guide RNAs target exon 1
immediately after the start ATG, thereby disrupting expression of
the 715-amino-acid full-length MX2 protein that possesses anti-
viral activity (the expression of a slightly shorter nonantiviral iso-
form initiating from a downstream ATG may still be possible).
Transduced THP-1 bulk populations expressing either of the two
guide RNAs displayed an approximately 5- to 8-fold reduced
block toHIV-1NL4.3GFPVSV-G infection after IFN- treatment
(Fig. 2A). As controls, we used parental THP-1 cells, as well as the
CRISPR/Cas9 control (Cntrl) cells, which had similar permissivity
to HIV-1 infection and expressed comparable MX1 andMX2 lev-
els after IFN- stimulation (Fig. 2A andB). In contrast, aMoloney
murine leukemia virus GFP vector, which is unaffected by ectopic
MX2 overexpression (32), was inhibited by IFN- in control cells
and MX2 CRISPR/Cas9 cells to similar extents (Fig. 2A).
Subsequently, single cell clones were derived in which MX2
expression after IFN- stimulation was either ablated (MX2g2-4)
or substantially reduced (MX2g1-1), whereas the IFN- signaling
pathway remained intact, as measured by MX1 induction (Fig.
2B).We validated gene disruption by PCR amplifying the targeted
genomic region and found that MX2g1-1 harbored two heterozy-
gous deletions, whereas MX2g2-4 had a homozygous deletion, in
both cases leading to disruption of the MX2 open reading frame
(data not shown).MX2g1-1, as well asMX2g2-4 and Cntrl THP-1
cells, showed no substantial difference in infection by wild-type
HIV-1 GFP reporter virus or CA mutants N74D or P90A in the
absence of IFN- prestimulation (Fig. 2C). In IFN--stimulated
THP-1 cells, infectivity of wild-type virus decreased 
10-fold,
whereas in MX2g1-1 and MX2g2-4 cells the infectivity was (as
expected) reduced only approximately 3- to 5-fold (Fig. 2C). In
contrast, infectivity of the N74D mutant decreased in IFN--
stimulated parental THP-1 cells 
43-fold and in MX2g1-1 and
MX2g2-4 cells 
20-fold (Fig. 2C). Similarly, HIV-1 P90A was
inhibitedmore strongly by IFN- treatment in parental THP-1, as
well as MX2 CRISPR/Cas9 cells, relative to the wild-type virus
(Fig. 2C). These data demonstrate that both HIV-1 CAN74D and
P90A are hypersensitive toMX2-independent IFN--induced an-
tiviral effectors.
HIV-1 N74D does not bind to the cleavage and polyadenyla-
tion specific factor 6 (CPSF6) and is insensitive to an artificially
truncated version of this protein (CPSF6-358) which blocks wild-
typeHIV-1 infection efficiently (49, 56, 57). To test whether a lack
in CPSF6 binding to CA could explain the enhanced sensitivity of
HIV-1 CA N74D mutant to IFN--induced blocks, we studied
HIV-1 CA A105T, another CPSF6-independent CA mutant. Like
N74D or P90A, HIV-1 A105T was less sensitive to inhibition by
ectopically expressed MX2 (data not shown). The A105T mutant
was inhibited
50-fold in THP-1 cells after IFN- pretreatment,
but like N74D, was not efficiently rescued from this block in cells
FIG 1 HIV-1 CA mutants N74D and P90A have increased sensitivity to IFN--induced suppression in diverse cell types. (A) THP-1 cells were pretreated with
increasing doses of IFN- and infected 24 h later with an equal amount of VSV-G-pseudotyped wild-type HIV-1 GFP lentiviral vector R8.91 or CA mutant
N74D or P90A, as measured by SG-PERT and 293T titration. At 48 h after infection the percentage of GFP-positive cells was determined by flow cytometry.
Infectivities in the absence of IFN- are shown on the left. The mean results from three independent experiments are shown. Error bars indicate the standard
deviations. For untreated cells, a nonpaired two-tailed t test was performed (ns, not significant; *, P 0.05; **, P 0.005). For IFN--treated samples, a paired
two-tailed t test with CI  0.95 was performed (wild type [WT] versus P90A, P  0.0001; WT versus N74D, P  0.0001). (B) Same as for panel A but with
NL4.3GFP-IRES-NEF (NL4.3GFP) viruses. Statistical evaluation was performed as in panel A (IFN--treated samples: WT versus P90A [P 0.0012] and WT
versus N74D [P 0.0002]). (C) Same as for panel A, but withMDMs from three independent donors. Error bars indicate the standard deviations. The statistical
tests were performed as in panel A (IFN--treated samples:WT versus P90A [P 0.0001] andWT versus N74D [P 0.0001]). (D) Same as for panel A, but with
CD4T cells from three independent donors. Error bars indicate the standard deviations. Statistical analyses were analogous to panel A (IFN--treated samples:
WT versus P90A [P 0.0001] and WT versus N74D [P 0.0001]).
Bulli et al.















lacking MX2 (Fig. 2C). We also observed increased sensitivity of
N74D or A105T viruses to IFN--induced blocks in PMA-differ-
entiated MX2 CRISPR/Cas9 THP-1 cells, as well as in MDMs,
indicating that these blocks function independently of cell prolif-
eration (data not shown). Together, these data raised the possibil-
ity that the interaction of incoming HIV-1 CA with CPSF6 may
help protect infection from MX2-independent IFN--induced
blocks.
CPSF6 does not contribute to the IFN--induced HIV-1
blocks.To address the possible role of CPSF6 in protectingHIV-1
from IFN--induced antiviral factors, we sought to determine
whether the sensitivity to IFN- was increased when CPSF6 pro-
tein levels were reduced. We therefore generated THP-1 CPSF6
CRISPR/Cas9 cells using four independent guide RNAs (CPSF6g1
to CPSF6g4). In stably transduced and drug selected bulk cultures
expressing CPSF6 gRNAs, IFN- treatment reduced HIV-1 GFP
reporter virus infectivity to the same extent as in parental cells
(
20-fold, data not shown). We next generated single cell
clones and proceeded with two lines with no CPSF6 expression
(CPSF6g2-1 and CPSF6g2-2) and one control clone (Cntrl) in
which CPSF6 expression matched that of parental cells, as well as
parental THP-1 (Fig. 3A). CPSF6 levels did not change upon
IFN- treatment in any of the cell clones (Fig. 3A).Wild-type and
N74D or A105T viruses showed similar titers in the untreated
parental, as well as CPSF6-depleted cell clones, and as expected,
the N74D or A105T viruses showed increased sensitivity to IFN-
pretreatment in all cells (Fig. 3B). Notably, the sensitivity of wild-
type HIV-1 to IFN- treatment was not increased in the CPSF6-
depleted cells, supporting a model in which CPSF6 binding to
incoming HIV-1 cores does not confer protection from type I
IFN-induced effectors (Fig. 3B). The increased sensitivity ofN74D
or A105T viruses to IFN- therefore cannot be explained by a lack
of CPSF6 binding. Unexpectedly, infection with all three viruses
wasmildly increased in CPSF6g2-1 and CPSF6g2-2 cells (Fig. 3B).
Given its cellular role, it is possible that the lack of CPSF6 perturbs
the mRNA processing and expression of ISGs involved in inhibit-
ing HIV-1.
IFN- induces an enhanced block to reverse transcription
and nuclear import ofHIV-1CAN74D.Wenext investigated the
stage(s) of infection that is blocked in MX2-depleted cells.
We measured the infectivities of VSV-G-pseudotyped wild-type
NL4.3GFP or the N74D mutant in THP-1 or CRISPR/Cas9
FIG 2 HIV-1 CAmutants are sensitized toMX2-independent IFN--induced blocks in THP-1 cells. (A) THP-1 cells were transduced withHIV-1 LVs encoding
a control gRNA (Cntrl) or two independent gRNAs against MX2 (g1 and g2) and then puromycin selected for 2 weeks. Parental THP-1 cells or transduced
CRISPR/Cas9 cell bulk populations were treated with 500 U/ml IFN- and challenged 24 h later with a serial dilution of NL4.3GFP VSV-G reporter virus or
Moloneymurine leukemia virus GFPVSV-G vector. The percentages of infectionweremeasured 2 days later by flow cytometry, and the relative infectivities were
determined. Bars indicate the average infectious titers determined from at least three independent viral doses normalized to untreated THP-1 cells, and error bars
indicate the standard deviations. Unpaired two-tailed t tests were performed (*, P  0.05; ***, P  0.001; ns, not significant). (B) Wild-type THP-1 cells, a
CRISPR/Cas9 control, and two independentMX2 knockout THP-1 single cell clones (g1-1 and g2-4) were treated with 500U/ml IFN-2 for 24 h. Immunoblots
of untreated or IFN--treated cells using antibodies specific for MX1 andMX2 are shown. Loading was controlled by measuring total protein by UV activation
of the gel. (C) Wild-type THP-1 and the MX2 knockout cell clones (g1-1 and g2-4) were treated for 24 h with 500 U/ml IFN- and then infected with a serial
dilution of VSV-G-pseudotyped NL4.3GFP wild-type, CA N74D or CA P90A or CA A105T mutant viruses. The figure shows infection measured at 48 h as in
panel A.
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MX2g2-4 cells (Fig. 4A) and in parallel isolated total DNA 4 or
24 h after infection to measure the amounts of GFP reverse
transcription product (Fig. 4B and C) or 2-LTR circles (Fig.
4D), respectively, by TaqMan quantitative PCR. As controls for
plasmid contamination, we used viral supernatants that had
been inactivated by boiling. The levels of GFP reverse tran-
scription products from HIV-1 wild-type virus decreased after
IFN- pretreatment 
4-fold at 4 h postinfection (Fig. 4B). In
contrast, the levels of GFP reverse transcription products for
HIV-1 CA N74D were reduced after IFN- treatment 
8-fold
and were not substantially different in MX2g2-4 cells com-
pared to parental THP-1 (Fig. 4B). We also observed a strong
reduction in copy numbers of GFP reverse transcription prod-
ucts 24 h postinfection for both the wild type and the N74D
mutant (Fig. 4C). In a parallel sample, we analyzed 2-LTR cir-
cles, a surrogate for HIV-1 nuclear import, at 24 h postinfec-
tion. We found that after IFN- pretreatment and wild-type
HIV-1 infection, 2-LTR circles were reduced in parental THP-1
cells 
30-fold, and only ~10-fold in MX2g2-4 cells, corrobo-
rating the role for MX2 in blocking nuclear import (Fig. 4D).
While for wild-type virus the 2-LTR circles were reduced 
9-
fold in IFN--treated MX2g2-4 cells, the 2-LTR circles for
N74D were blocked by almost 2 orders of magnitude (Fig. 4D).
Therefore, the increased IFN--induced block to N74D infec-
tion (Fig. 4A) can be explained by a stronger reduction in re-
verse transcription products (Fig. 4B and C) and reduced ac-
cumulation of 2-LTR circles, reflecting the suppression of
nuclear import (Fig. 4D). In conclusion, our data suggest that
wild-type CA protects HIV-1 from MX2-independent IFN--
induced factors that target reverse transcription and nuclear
FIG 3 CPSF6 knockout in THP-1 cells does not increase sensitivity to IFN--
induced blocks to HIV-1. (A) Parental THP-1 cells or three independent
CRISPR/Cas9 cell clones of which two did not express CPSF6 (g2-1 and g2-2)
were treated 24 h with IFN- or left untreated. The next day, whole-cell lysates
were used in immunoblotting experiments to detect CPSF6 expression levels.
MX2 expression served as a control for IFN- treatment. (B) In parallel, cells
were infected 24 h after IFN- treatment with a serial dilution of VSV-G
pseudotyped wild-type NL4.3GFP or the CA mutants N74D or A105T. The
average infectious titers (i.u./URT) of three virus doses are shown, and error
bars indicate the standard deviations.
FIG 4 Hypersensitivity of the HIV-1 CA mutant N74D to IFN- occurs at the stages of reverse transcription and nuclear import. Parental THP-1 or MX2g2-4
CRISPR/Cas9 cells were infectedwithVSV-G-pseudotypedNL4.3GFPwild-type orN74DCAmutant virus. (A)At 24 h after infection, the percentages ofGFP-positive
cellsweredeterminedbyflowcytometry. (B toD)In twoparallel samples, totalDNAwasextracted4h(B)or24h(C)postinfectionandsubjected toTaqManquantitative
PCR using a primer/probe set specific for GFP or 2-LTR circles (D). As a control for plasmid contamination, boiled virus was used. The averages of two independent
experiments are shown.
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import and that the CA changes increase sensitivity to inhibi-
tion by these factors.
Host cell cyclophilins regulate IFN--induced blocks to
HIV-1. Since we observed an increased sensitivity of the P90A CA
mutant virus to IFN--inducedMX2-independent antiviral effec-
tors (Fig. 1), we hypothesized that the host protein cyclophilin A
(CypA), which can isomerize the G89-P90 peptide bond inHIV-1
CA, might affect IFN--induced blocks. CypA is a target for the
immunosuppressive drug cyclosporine (Cs), as well as for nonim-
munosuppressive compounds such as SDZ-NIM811. In the pres-
ence of Cs or SDZ-NIM811, virus infectivity is often reduced,
suggesting that CypA and possibly other cyclophilins may act as
cofactors that promote HIV-1 infection (59, 69, 77–80). We
treated THP-1 cells with serial dilutions of IFN- for 24 h, chal-
lenged them with VSV-G-pseudotyped HIV-1 GFP LV in the
presence of increasing amounts of Cs, and determined the levels of
infection at 2 days postinfection. Unexpectedly, we found that Cs
addition rescued HIV-1 LV infectivity in a dose-dependent man-
ner, e.g., the infectivity was increased
10-foldwith 5MCs (Fig.
5A). To rule out an immunosuppressive effect mediated through
calcineurin (81), we analyzed whether the nonimmunosuppres-
sive Cs analogue SDZ-NIM811 (77) would also rescue infectivity.
We treated THP-1 cells for 24 h with IFN- and then infected
them with a single dose of HIV-1 GFP LV in the presence of in-
creasing doses of SDZ-NIM811 up to 5 M. Similar to Cs, SDZ-
NIM811 rescued the infectivity of wild-type HIV-1 LV from the
IFN--induced block (Fig. 5B), suggesting that the reversion of
IFN--induced inhibition of HIV-1 infection was independent of
the immunosuppressive activity of Cs.
The reduction of CypA levels or pharmacologic inhibition by
the provision of Cs, as well as CA manipulation to escape CypA
binding, has been shown to overcome the antiviral effect of MX2
(34). The efficient rescue of HIV-1 GFP LV infectivity from the
IFN--induced blocks in THP-1 cells by Cs (Fig. 5A) suggested
that Cs could affect both the blockmediated throughMX2 and the
MX2-independent IFN--induced blocks. To investigate this, we
incubated parental THP-1 cells or the MX2-deficient lines
MX2g1-1 or MX2g2-4 with IFN- for 24 h and challenged them
with VSV-G-pseudotyped HIV-1 GFP LV in the presence or ab-
sence of Cs. We observed a rescue of virus infectivity in THP-1
cells and inMX2-deficient cell clones byCs (Fig. 5C). Surprisingly,
whenwe testedVSV-G-pseudotypedHIV-1GFPLVP90A in IFN-
-stimulated cells, we also observed an increased infectivity in the
presence of Cs (Fig. 5D). These data demonstrate that the MX2-
independent IFN--induced blocks are sensitive to Cs.
Cs does not exclusively target CypA but can also bind and
inhibit other cyclophilins. Therefore, we decided to investigate
whether CypA gene disruption would either increase the sensitiv-
ity of wild-type HIV-1 to IFN-, phenocopying the P90Amutant,
or would rescue wild type virus infectivity from the IFN--in-
duced block, as observed with Cs treatment.We generated THP-1
cell clones in whichCypAwas disrupted using CRISPR/Cas9 tech-
nology. CypA expression was eliminated in three different clones,
as judged by immunoblotting (Fig. 5E). These stable cell clones
were pretreated with a serial dilution of IFN- for 24 h and chal-
lenged with VSV-G-pseudotyped NL4.3GFP or the correspond-
ing CA mutant virus NL4.3GFP P90A. CypA gene disruption had
no major effects on the infectivities of wild-type or P90A mutant
virus in the absence of IFN- stimulation. In contrast, after IFN-
treatment, the infectivity of wild-type virus was reduced
5-fold
more in THP-1 cells lacking CypA than that in parental or Cntrl
cells (Fig. 5F). The infectivity of the P90A mutant virus was re-
duced by IFN- to similar levels in all cell lines, suggesting that the
P90A mutant phenocopied wild-type infections in the absence of
CypA (Fig. 5E and F).
Because these data indicated that CypA gene disruption andCs
treatment had opposing effects on the infectivity of HIV-1 in the
presence of IFN-, we needed to rule out a role of CypA in the Cs-
mediated increase of HIV-1 infectivity. We stimulated the THP-1
cell clones lacking CypA with a serial dilution of IFN- and chal-
lengedwithwild-typeHIV-1GFPLV in the presence or absence of
Cs. Strikingly, Cs also rescued HIV-1 infectivity from the IFN--
induced block in cells lacking CypA (Fig. 5G). Collectively, these
findings indicate that whereas CypA helps protect incoming
HIV-1 cores from IFN--induced antiviral factors, the activity of
other cyclophilins contributes substantially to the IFN--induced
block in THP-1 cells.
DISCUSSION
HIV-1 infection is blocked during reverse transcription by IFN-
pretreatment of certain cell types, including CD4 T cells and
MDMs (30). The physiological importance of type I IFNs during
the early course ofHIV-1 infection is evidenced by the observation
that certainT/F viruses replicatemore efficiently in the presence of
IFN- than in their viral counterparts from chronic infection (22,
23). Likewise, the plasma SIV viral load in acutely infected ma-
caques was increased by the addition of a type I IFN receptor
antagonist, arguing for an important functional role of type I IFN
in suppressing viral replication during the acute phase (3). In ad-
dition, clinical trials have demonstrated reductions in viral load
during IFN- treatment, making therapy strategies incorporating
IFN- treatment attractive (82, 83). However, plasma HIV-1
RNA rebounds to a degree after several weeks, suggesting HIV-1
escape from, or desensitization to, IFN--induced antiviral effec-
tors (83). The viral determinants for the differential sensitivity to
type I IFN-induced blocks are currently unknown.
Here, we analyzed the sensitivity of HIV-1 CAmutants N74D,
A105T, as well as P90A, to IFN--induced blocks and found that
their infectivities were reduced further after IFN- treatment of
THP-1 cells, MDMs, or CD4 T cells than that of wild-type virus
(Fig. 1), despite their relative resistance to ectopically expressed
MX2 (32–34). Using genetic knockout, the increased sensitivity of
the HIV-1 CAmutants to IFN--induced blocks was shown to be
independent of MX2 (Fig. 2) and occurred during reverse tran-
scription (Fig. 4), suggesting that alterations in CA may lead to
enhanced interactions between IFN--induced antiviral effectors
and CA (perhaps as a consequence of slower capsid uncoating
[84]) and/or to detrimental exposure of reverse transcription
complexes to such effectors. During the preparation of the man-
uscript, Opp et al. reported that MX2 gene disruption had no
restorative effect on HIV-1 infectivity from an IFN--induced
block in THP-1 cells (85). Our results differ substantially and con-
firm that IFN- induces at least two blocks, the first one at the level
of reverse transcription (30), which is sensitive to changes in CA,
and the second one at the level of nuclear import and involving
MX2 (32).
Disruption of CypA by CRISPR/Cas9 modestly increased
the sensitivity of HIV-1 to IFN--induced blocks, indicating
that CypA interactions with incoming capsids may help to pro-
tect HIV-1 from IFN--induced antiviral effectors in THP-1
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FIG 5 Cyclophilins affect the sensitivity ofHIV-1 to IFN--induced effectors inTHP-1 cells. (A)THP-1 cells were treated for 24 hwith a serial dilution of IFN-before
infectionwithVSV-G-pseudotypedwild-typeHIV-1GFP vector (R8.91) in the presence of increasing amounts of Cs inDMSO.The percentages of infected cells were
measured48h laterbyflowcytometry.Representative results fromthree independent experiments are shown. (B)THP-1cellswere treated for24hwith100U/ml IFN-
or leftuntreatedand then infectedwitha singledoseofVSV-G-pseudotypedwild-typeHIV-1GFPLVin thepresenceof increasingamountsof thecyclosporineanalogue
SDZ-NIM811. The percentages of infected cells were determined as in panel A. Representative results from three independent experiments are shown. (C) Parental
THP-1 cells orMX2 CRISPR/Cas9 cell clones were pretreated with 500 U/ml IFN- for 24 h and then infected with a serial dilution of VSV-G-pseudotyped wild-type
HIV-1GFPLV in the presence or absence of 5MCsorDMSOas a control, and the percentages ofGFP-positive cellswere determined as in panelA.Average infectious
titers for threeviraldoses are shown.Errorbars indicate the standarddeviations. (D)THP-1cellswere treated for24hwith500U/ml IFN-and then infectedwitha serial
dilution of VSV-G-pseudotyped wild-type or CA P90Amutant HIV-1 GFP LV in the presence or absence of 2.5MCs orDMSO as a carrier control. The percentages
of infected cells were determined as in panel A. (E)THP-1 cells were transducedwith a vector expressing aCRISPR/Cas9 guideRNAagainstCypA, and individual single
cell cloneswere tested. Immunoblottingof cell lysates fromparental THP-1 aswell as three independentTHP-1CypACRISPR/Cas9 cell clones detectingCypAandwith
MAPKas a loading control. (F) Parental THP-1 cells, Cntrl cells, orCypACRISPR/Cas9 cell cloneswere treatedwith a serial dilutionof IFN- for 24 h and then infected
with VSV-G-pseudotyped wild-type or CA P90Amutant NL4.3GFP at similar doses. The percentages of infected cells were determined as for panel A, and normalized
infectivities were determined in the absence of IFN- treatment. The average relative infectivities of three independent experiments are shown. Error bars indicate the
standarddeviations. Fordataderived fromIFN--treated samples, a paired two-tailed t testwith confidence interval of 0.95wasperformed (HIV-1NL4.3GFPwild type:
Cntrl versus CypAg1-1 [**, P 0.0047]; Cntrl versus CypAg1-2 [**, P 0.0058]; Cntrl versus CypAg1-3 [***, P 0.0002]; NL4.3GFP P90A: Cntrl versus CypAg1-1
[n.s.];Cntrl versusCypAg1-2 [n.s.];Cntrl versusCypAg1-3 [n.s.];Cntrl cells:NL4.3GFPwild type versusNL4.3GFPP90A[***,P0.0001]).Without IFN- treatment,
no significant differences between Cntrl cells and CypAg1-1, CypAg1-2, or CypAg1-3 were detected for both NL4.3GFP wild type and NL4.3GFP P90A. (G) Parental
THP-1 cells, Cntrl cells, or CypACRISPR/Cas9 cell clones were treated with a serial dilution of IFN- for 24 h and then infected with VSV-G-pseudotypedHIV-1GFP
LVin thepresenceof5MDMSOorCs, and thepercentagesof infectedcellsweredeterminedas forpanelA.Representative results fromthree independent experiments
are shown.
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cells (Fig. 5). In contrast, genetic disruption of CPSF6 did not
increase the sensitivity of wild-type or CA mutant HIV-1 to
IFN--induced effectors in THP-1 cells (Fig. 3), arguing that
CPSF6 does not play a role in protecting infection from IFN-
-induced blocks (49, 58). The findings therefore differ from
what has been described for cGAS sensing of HIV-1 where both
CypA and CPSF6 are thought to play protective roles (53).
However, the replication defects of N74D and P90A viruses in
MDMs may be explained by a combination of increased cGAS
sensing, IFN- induction, and increased sensitivity to the IFN-
-induced effectors themselves.
Our data suggest that at least one other Cs-sensitive cyclophi-
lin, other than CypA, is directly or indirectly involved in the IFN-
-induced early block to HIV-1. Other cyclophilins for which
evidence suggests interactions with HIV-1 proteins include PPIB
(62), PPIE and PPIF (86), and PPIH (87). The nuclear pore com-
plex component NUP358, a cofactor for HIV-1 early infection
steps, has a cyclophilin domain at its carboxy terminus; however,
this domain does not efficiently interact with Cs, making it un-
likely that NUP358 is involved in the Cs/SDZ-NIM811-mediated
rescue of infectivity from IFN--induced blocks (51, 65). Screen-
ing the interferome database (88) revealed that human peptidyl-
prolyl isomerase F (PPIF) transcripts were upregulated 2-fold
when CD14 monocytes were treated with 10,000 IU/ml IFN-
(data set IFM30) and mouse Nktr and Ranbp2 were upregulated
2.6- and 3.4-fold, respectively, by 10,000 IU/ml IFN- (data set
IFM34). To our knowledge, these are the only cyclophilins that
have been suggested to be upregulated by type I IFNs. Impor-
tantly, Cs addition also rescued HIV-1 P90A infectivity with an
efficiency similar to that of thewild type (Fig. 5D), arguing that the
G89-P90 peptide bond in the cyclophilin-binding loop of CA is
not the responsive viral determinant.
Multiple lines of evidence suggest that CA mutants N74D,
A105T or P90A have defects in capsid stability and uncoating,
possibly due to altered interactions with host factors. First, cDNA
reverse transcription intermediates of both N74D and P90A mu-
tant viruses are sensed and trigger type I IFN production after
infection of MDMs (53). Second, N74D shows delayed uncoating
kinetics inTRIMCyp-expressing cells and aCswashout assay (89),
suggesting that this mutation perturbs uncoating (84). Third,
N74D is more susceptible to the NNRTI nevirapine compared to
wild-type virus, suggesting that wild-type capsid integrity may
help protect the virus fromantiviral drugs (55). Fourth,HIV-1CA
P90A binds CypA with reduced affinity (51, 60), such that the
stabilizing effects of CypA binding to CA are lost (90, 91). Fifth,
the A105T mutation, though outside the cyclophilin-binding
loop, can affect viral sensitivity to Cs (92–95). Finally, all three CA
mutants change the requirement for specific NPC-associated pro-
teins during infection, suggesting that events before reaching the
NPC are altered (49). Whether cytoplasmic trafficking is dis-
turbed for HIV-1 CA mutants is unclear at the moment (96).
Accordingly, interactions with cellular factors, as well as the in-
trinsic properties of incoming viral capsids, are affected by these
particularmutations, one consequence of which is the greater sen-
sitivity of relevant mutant viruses to IFN--induced infectivity
blocks.
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